Perspective Therapeutics, Inc. 8-K

What Happened

• Perspective Therapeutics, Inc. (CATX) filed an 8-K reporting results from its Annual Meeting held May 27, 2026. Shareholders representing 97,882,462 of 114,017,755 outstanding shares (85.85%) were present or represented by proxy.
• Six director nominees were elected to the board to serve until the 2027 annual meeting: Lori A. Woods; Heidi Henson; Maya Martinez-Davis; Frank Morich, M.D., Ph.D.; Johan (Thijs) Spoor; and Robert Froman Williamson, III. The filing lists vote totals (For, Withheld, and Broker Non-Votes) for each nominee.
• Stockholders ratified the appointment of WithumSmith+Brown, PC as the company’s independent registered public accounting firm for fiscal 2026 (For: 97,636,978; Against: 125,426; Abstain: 120,058).
• On a non‑binding advisory vote on the frequency of future advisory votes on executive compensation (say-on-pay), shareholders favored annual votes (1 year: 76,479,166 vs. 2 years: 274,495; 3 years: 364,497). The Board intends to hold annual advisory votes going forward.

Key Details

• Quorum: 97,882,462 shares represented, or 85.85% of 114,017,755 outstanding shares.
• Director vote highlights: Maya Martinez‑Davis received 77,085,447 votes For; Frank Morich received 62,317,819 votes For and 14,965,406 Withheld.
• Auditor ratification vote: WithumSmith+Brown, PC ratified with 97,636,978 For votes.
• Advisory vote on compensation frequency: 76,479,166 voted for annual (1‑year) votes; there were 20,599,237 broker non‑votes recorded on the compensation frequency item.

Why It Matters

• Board continuity and governance: Re-election of the six directors maintains the company’s current board composition through the 2027 annual meeting, which can affect strategic oversight and management continuity.
• Auditor confirmation: Ratification of WithumSmith+Brown, PC confirms the auditor for fiscal 2026, an item investors often watch for accounting continuity and audit quality.
• Shareholder preference for annual say-on-pay: Although advisory (non‑binding), the clear vote for annual executive‑compensation votes signals strong shareholder interest in regular, transparent review of executive pay; the Board has agreed to hold annual votes.